Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab, Endostar, and Oncorine in Advanced NSCLC
NCT06618391Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Oct 2024
- Primary completion
- Mar 2026
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
01
Overview
Phase 2, randomised, open-label trial of envafolimab, endostar and Oncorine in non-small cell lung cancer (NSCLC), sponsored by Henan Cancer Hospital. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
envafolimabendostarOncorine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06618391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06618391.